Mirion Technologies

Mirion Technologies, Inc. engages in the provision of nuclear measurement and detection systems. It offers measurement and enterprise, calibration, customer training programs, installation, product support and repairs, consulting, and instadose desimetry services. The company was founded by Thomas D. Logan in December 2005 and is headquartered in Atlanta, GA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirion Technologies posts robust Q4 earnings, eyes SMR market growth

Mirion Technologies reported strong financials, with double-digit revenue growth and a focus on reducing leverage, despite challenges like supply chain issues.
The company's strategic focus on the Medical and Industrial segments, along with opportunities in the SMR market, bode well for future growth.
Balanced growth strategies, disciplined capital allocation, and engagement in key markets position Mirion Technologies for continued success in 2023.

Mirion Technologies reports robust Q1 earnings, eyes growth opportunities

Mirion Technologies delivered strong Q1 results, focusing on operational efficiency, margin improvement, and cash flow generation. The company's rebranding efforts and positive market outlook position it well for future growth. With a history of margin expansion and free cash flow conversion, Mirion is poised for continued success in 2023.

Mirion Technologies posts robust Q2 results and eyes growth opportunities

Mirion Technologies delivered strong Q2 results with positive revenue growth and operational performance.
The company's focus on margin improvement and order intake positions it well for future success.
Despite challenges in pricing dynamics and cash flow, Mirion Technologies remains optimistic about its outlook.

Mirion Technologies excels in Q3 with strong order growth and record backlog

Mirion Technologies delivered a strong Q3 performance with significant order growth and record backlog, supported by strategic acquisitions and operational focus.
While facing challenges in organic growth and margin maintenance, the company remains optimistic about future opportunities for revenue expansion and profitability.
Maintaining financial targets, optimizing cash flow, and emphasizing margin expansion are key priorities for sustained success and market leadership.

Mirion Technologies reports record 2023 results and bullish 2024 guidance

Mirion Technologies had a stellar 2023, setting records in revenue, EBITDA, and free cash flow, with strong guidance for 2024.
The company is strategically focused on margin expansion, cost control, and product innovation to drive future growth.
While facing challenges in healthcare reimbursement and cost management, Mirion is leveraging international markets and new product introductions.
Confidence in achieving growth targets, Mirion remains committed to operational excellence and enhancing shareholder value.

Mirion Technologies reports solid Q1 performance, eyes growth opportunities

Mirion Technologies demonstrated strong financial performance in Q1 2024, driven by key growth drivers in nuclear power and cancer care. Despite challenges in cash flow and margin pressure, the company remains focused on growth opportunities through innovation and strategic initiatives.

Mirion Technologies reports solid Q2 results, eyes growth opportunities

Mirion Technologies showcased solid performance with margin exceeding expectations and raised EBITDA guidance. While facing tough order growth comps, the company is focused on driving organic growth and improving cost structure. Anticipated improvements in Chinese market dynamics and potential positive impact from upcoming CMS changes present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirion Technologies, Inc. engages in the provision of radiation safety, science, and medicine. It operates through the Medical and Technologies segments. The Medical segment consists of sales, products, and services to customers in the medical market. The Technologies segment involves nuclear energy, defense, laboratories, and scientific research markets as well as other industrial markets. The company was founded by Thomas D. Logan in December 2005 and is headquartered in Atlanta, GA.

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR), a leading provider of detection, measurement, analysis and monitoring solutions to the nuclear, defense, medical and research end markets, announced that its Class A common stock and warrants will begin trading on the New York Stock Exchange today under the symbols “MIR” and “MIRW,” respectively. Management will participate in a closing bell ceremony at the New York Stock Exchange today, October 21, 2021, in celebration

Mirion Technologies Begins Trading on the New York Stock Exchange Under the Symbol “MIR”

News for Mirion Technologies Stock (MIR)